Articles

< Previous         Next >  
Tumor-derived microvesicles mediate human breast cancer invasion through differentially glycosylated EMMPRIN 
Kerstin Menck1, Christian Scharf2,3, Annalen Bleckmann1, Lydia Dyck1, Ulrike Rost4, Dirk Wenzel5, Vishnu M. Dhople3, Laila Siam6, Tobias Pukrop1, Claudia Binder1,†, and Florian Klemm1,7,†,*
1Department of Hematology/Oncology, University Medical Center Göttingen, 37099 Göttingen, Germany
2Department of Otorhinolaryngology, Head and Neck Surgery, University Medicine Greifswald, Walther-Rathenau-Str. 43-45, 17475 Greifswald, Germany
3Department of Functional Genomics, Interfaculty Institute for Genetics and Functional Genomics, Ernst-Moritz-Arndt University Greifswald, Friedrich-Ludwig-Jahn-Str. 15, 17487 Greifswald, Germany
4Institute for Organic and Biomolecular Chemistry, University of Göttingen, Tammannstrasse 2, 37077 Göttingen, Germany
5Max Planck Institute for Biophysical Chemistry, Am Fassberg 11, 37077 Göttingen, Germany
6Department of Neurosurgery, University Medical Center Göttingen, 37099 Göttingen, Germany
7Present address: Sloan Kettering Institute, Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, 417 E 68th St., Z-1306, New York, NY 10065, USA *Correspondence to:Florian Klemm, E-mail: klemmf@mskcc.org
J Mol Cell Biol, Volume 7, Issue 2, April 2015, 143-153,  https://doi.org/10.1093/jmcb/mju047
Keyword: breast cancer,microvesicles,invasion,EMMPRIN,glycosylation

Tumor cells secrete not only a variety of soluble factors, but also extracellular vesicles that are known to support the establishment of a favorable tumor niche by influencing the surrounding stroma cells. Here we show that tumor-derived microvesicles (T-MV) also directly influence the tumor cells by enhancing their invasion in a both autologous and heterologous manner. Neither the respective vesicle-free supernatant nor MV from benign mammary cells mediate invasion. Uptake of T-MV is essential for the proinvasive effect. We further identify the highly glycosylated form of the extracellular matrix metalloproteinase inducer (EMMPRIN) as a marker for proinvasive MV. EMMPRIN is also present at high levels on MV from metastatic breast cancer patients in vivo. Anti-EMMPRIN strategies, such as MV deglycosylation, gene knockdown, and specific blocking peptides, inhibit MV-induced invasion. Interestingly, the effect of EMMPRIN-bearing MV is not mediated by matrix metalloproteinases but by activation of the p38/MAPK signaling pathway in the tumor cells. In conclusion, T-MV stimulate cancer cell invasion via a direct feedback mechanism dependent on highly glycosylated EMMPRIN.